Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | MMP13 | P45452 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16598258 | 0.87 | HTT (0.76) | HTTMMP13POLBUSP2TSHR | |
| SCHEMBL16598250 | 0.87 | HTT (0.76) | HTTMMP13POLBTSHRHPGD | |
| SCHEMBL30142987 | 0.86 | HTT (0.75) | HTTMMP13POLBKMT2ASMN1; SMN2 | |
| SCHEMBL3083971 | 0.86 | HTT (0.75) | HTTMMP13TSHRHPGDKMT2A | |
| SCHEMBL29733373 | 0.86 | HTT (0.75) | HTTMMP13TSHRHPGDKMT2A | |
| Hydrochloric Acid SCHEMBL27924615 | 0.84 | HTT (0.73) | HTTMMP13TSHRHPGDKMT2A | |
| SCHEMBL30143012 | 0.84 | HTT (0.72) | HTTMMP13POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL13728048 | 0.84 | MMP13 (0.77) | HTTMMP13POLBUSP2TSHR | |
| SCHEMBL7986921 | 0.83 | HTT (0.71) | HTTMMP13TSHRHPGDKMT2A | |
| SCHEMBL1316772 | 0.83 | HTT (0.71) | HTTMMP13POLBTSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144743-A1 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-05-28 | — | — | US | disclosed |
| US-12612368-B2 | Cancer treatments targeting cancer stem cells | REMEDY PLAN, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12377105-B2 | Compounds | TMEM16A LIMITED (GB) | 2025-08-05 | — | — | US | disclosed |
| CN-119930509-A | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-114929672-B | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2025-01-21 | — | — | CN | disclosed |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20230023124-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20220395512-A1 | COMPOUNDS | TMEM16A LTD (GB) | 2022-12-15 | — | — | US | disclosed |
| EP-4055008-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | Remedy Plan, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| CN-114929672-A | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144743-A1 | COMPOUNDS | CACNA1E, TMEM109, CACNA1C | HTT 1124/4885MMP13 3066/4885POLB 4023/4885 |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | HTT 1751/4885MMP13 4755/4885POLB 4192/4885 |
| US-20220395512-A1 | COMPOUNDS | CACNA1E, TMEM109, CACNA1A | HTT 2593/4885MMP13 4372/4885POLB 2519/4885 |
| US-12612368-B2 | Cancer treatments targeting cancer stem cells | MALT1, BCOR, MCL1 | HTT 2021/4885MMP13 2757/4885POLB 2309/4885 |
| US-12377105-B2 | Compounds | CACNA1E, TMEM109, CACNA1A | HTT 2593/4885MMP13 4372/4885POLB 2519/4885 |
| US-20230023124-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, KIT, GLI1 | HTT 991/4885MMP13 1299/4885POLB 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.